论文部分内容阅读
器官移植是目前终末期器官衰竭患者的主要替代治疗手段.免疫抑制剂的应用虽然降低了器官移植后急性排斥反应的发生率,但是并没有从根本上改善移植受者的长期生存.究其原因,主要是由于非特异性免疫抑制剂的毒副作用所致.因而减少免疫抑制剂毒副作用的最理想方案是诱导机体免疫耐受的形成,但是目前在临床上还无法常规实现.近期有研究证实,外源性α-1抗胰蛋白酶能明显减轻肝脏、胰腺、肺等器官移植的缺血再灌注损伤引起的凋亡和炎症,为器官移植的保护性研究提供了新的方向.“,”Organ transplantation is currently the main alternative treatment for patients with end-stage organ failure.Immunosuppressive therapy after organ transplantation deaceases the incidence of acute rejection reaction,but it cannot improve the long-term survival of transplant recipients.The reason is mainly due to the side effects caused by non-specific immunosuppressive agents.The idem way to reduce the side effects of immunosuppressive is to induce immune tolerance.However,induction of immune tolerance is not currently implemented in routine clinical practice.Recent studies have demonstrated that exogenous α-1 antitrypsin can significantly reduce the injury and inflemmation caused by the liver,pancreas,lung and other organ transplantation ischemia reperfusion.